Who is sponsoring NCT05267366?

NCT05267366 is sponsored by Qingdao Central Hospital.

What drugs are being tested in NCT05267366?

Interventions in NCT05267366: PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed.

Is NCT05267366 still recruiting?

NCT05267366 is currently status unknown. Last updated 29 March 2023.

Last reviewed 2023-03-29 · How we verify

NCT05267366

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC

Status unknown Phase 2 Last updated 29 March 2023

What this trial tests

Phase 2 trial testing PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed in PFS in 117 participants. Status unknown.

Timeline

1 February 2022

Primary endpoint
1 February 2024

1 July 2024

Quick facts

Lead sponsor	Qingdao Central Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	117
Start date	1 February 2022
Primary completion	1 February 2024
Estimated completion	1 July 2024
Sites	1 location across China

Drugs / interventions tested

PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed — full drug profile →

Conditions studied

PFS — all drugs for PFS →
OS — all drugs for OS →

Sponsor

Qingdao Central Hospital

Who can join

Adults 18 to 80, any sex, with PFS or OS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In recent years, immunotherapy has emerged as a form of treatment that can lead to robust responses in a subset of patients. PD-1 inhibitor plus chemotherapy showed prolonged survival in NSCLC by the study of KEYNOTE 024, KEYNOTE 189 etc. Thus, this study combines immunotherapeutic agent PD-1 inhibitor with an ant-angiogenic agent, bevacizumab, and double platinum therapy (carboplatin/cisplatin and pemetrexed).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Qingdao Central Hospital trials

Trials by the same sponsor.

NCT07090031 — Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer · Phase 2 · active not recruiting
NCT07090525 — Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions · Phase 2 · recruiting
NCT07322783 — Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification · Phase 2 · recruiting
NCT06500234 — Nutrition Impact on Immunotherapy of Cancer · Phase 3 · recruiting
NCT06514118 — Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05267366 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qingdao Central Hospital
Last refreshed: 29 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05267366.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing